Background: The risk of skin cancer in patients with HIV has not been extensively studied.
Skin cancer risk is increased in immunocompromised individuals. 1, 2 After the introduction of highly active antiretroviral therapy (HAART), the overall life expectancy for well-treated patients with HIV is approaching that of the background population. 3 The immunologic recovery resulting from HAART has lowered the incidence of AIDS-defining cancers while there is a persistently increased risk of some noneAIDS-defining cancers. 4 Whether patients with HIV are at increased risk of skin cancer is not well documented, in part because few countries provide reliable information on keratinocyte skin cancers (KSCs), in particular basal cell carcinoma (BCC). A 2-fold increased risk of BCC and squamous cell carcinoma (SCC) was shown in a study of patients with HIV living in the United States. 5 In this study, we aim to estimate the risk of noneAIDS-defining skin cancer, both KSCs (BCCs and SCCs) and malignant melanoma (MM) in patients with HIV compared with a sex-and age-matched cohort from the background population as well as siblings of these 2 cohorts. This unique study design using high-quality, populationbased, nationwide data enabled us to address potential confounding by skin type and family-related sun behavior and to provide data on skin cancer risk in patients with HIV from more northern parts of the world.
METHODS
The study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). We used 4 national registries as data sources after approval from the Danish Data Protection Agency. According to Danish law, no human participant committee approval is required for register-based studies.
Setting
The Danish population consists of 5.7 million inhabitants 6 with an estimated adult HIV prevalence of 0.1%. Patients with HIV are treated in 8 specialized HIV centers and are followed on an outpatient basis every 12 to 24 weeks. Antiretroviral treatment is provided free of charge to all residents of Denmark with HIV.
Data sources
We used the unique 10-digit civil registration number assigned to all individuals in Denmark 7 to link the data sources described below.
The Danish HIV Cohort Study
The Danish HIV Cohort Study (DHCS) is a prospective, nationwide, population-based cohort study of all patients with HIV who are $16 years of age at the time of diagnosis and who were treated at Danish HIV centers since January 1, 1995 with consecutive ongoing enrollment. 8 A detailed description of the cohort has previously been published. 9 Annual updates are performed, and date of first positive HIV test and start of antiretroviral treatment (HAART) are important cohort parameters as well as route of infection, CD4 cell counts, and HIV RNA measurements.
The Danish Civil Registration System
Established in 1968, the Danish Civil Registration System stores information of vital status and demographic data on all Danish citizens. 7 We collected date of birth, sex, loss to follow-up, and death from this register.
The Danish Cancer Register
The Danish origin from the background population (''the matched background cohort'') who were alive and living in Denmark at the date of inclusion. Danish origin was defined as one or both parents being born in Denmark and having Danish citizenship. This restriction by country of origin was applied to reduce potential bias by differences in skin type between patients with HIV and the matched background population. Date of inclusion was defined as January 1, 1995 or first date of HIV diagnosisd whichever came last. We excluded patients who had skin cancer before study enrollment.
For both patients with HIV and the matched background cohort we included siblings in 2 sibling cohorts. In the Danish Civil Registration System, parents' civil registration number is included for [99% of persons born after 1952, less in persons born before. 11 We included siblings if they had at least 1 common parent and were alive and living in Denmark at time of study inclusion.
Outcome
The primary study outcome was time to first BCC, SCC, or MM. We identified the skin cancers using the International Classification of Diseases, 10th Revision diagnoses C43.0 to C439 (for MM) and C44.0 to C44.9 (for BCC and SCC) coupled with the following morphology codes: M80902, M80903, M80923, and M80933 (for BCC) and M80703, M80713, M80743, M80753, and M80763 (for SCC). SCCs and MMs in other locations than the skin were not included.
Statistical analysis
Person-years at risk (PYR) were calculated as time from study inclusion to the date of first cutaneous cancer, death, loss to follow-up, emigration, or December 31, 2014, whichever came first.
Incidence rates (IR) with corresponding 95% confidence intervals (CIs) were calculated for BCC, SCC, and MM. By subtraction, differences in each outcome between the patient and background cohorts were calculated with corresponding 95% CIs. Incidence rate ratios (IRRs) of skin cancer for patients with HIV compared with the matched background cohort were estimated using Poisson regression models. To address potential association with immunosuppression, we fitted a Poisson regression model for patients with HIV only where the following variables were considered: current CD4 cell count \350 cells/L (time updated variable), ever exposed to HAART (time updated variable), nadir CD4 cell count before study inclusion, sex, and age. Few patients were diagnosed with skin cancer before first treatment with HAART, and therefore in the final analysis we only included patients with HIV who were exposed to HAART. Therefore, we were unable to address the impact of HAART. Consequently, in the final model, IRRs were estimated for current CD4 cell count (\350 vs $350 cells/L), nadir CD4 cell count (per cell/L increase), sex, and age (per year increase).
To investigate potential confounding from familyrelated factorsdin particular, the level of sun exposure during childhood and skin typedwe compared the risk of skin cancer between siblings of patients with HIV and siblings of the matched background cohort. In addition, all analyses were stratified by route of infection (men who have sex with men [MSM] vs other routes of infection), because it has been suggested that MSM with HIV have increased recreational sun exposure. 12 The cumulative incidence function was used to estimate the absolute risk of KSC, with death handled as a competing risk. 13 
RESULTS
Of the 6323 patients with HIV in the DHCS, we excluded 2043 (32.3%); the majority were excluded because they were from a country other than Denmark. This left 4280 patients with HIV who were followed for [41,000 PYRs. We identified 21,399 individuals for the matched background cohort who were followed for [274,000 PYRs. Descriptive data can be seen in Table I .
Risk of BCC
The IR of BCC was 2.43 (95% CI 2.00-2.95) per 1000 PYRs in patients with HIV and 1.43 (95% CI 1.30-1.58) per 1000 PYRs in the matched background cohort, with a difference of 1.00 (95% CI 0.50-1.49) per 1000 PYRs (Table II) . Neither current nor nadir CD4 cell count was associated with a risk of BCC (Table III) .
The risk of BCC differed according to route of infection. Those who reported MSM as the route of HIV transmission had an increased risk of BCC with an IRR of 2.30 (95% CI 1.76-3.02) compared with the matched background cohort. No increased risk of BCC was observed for other routes of HIV infection (Table II) .
Risk of SCC
The IR of SCC was 0.50 (95% CI 0.32-0.77) per 1000 PYRs in HIV-infected patient and 0.10 (95% CI 0.07-0.15) per 1000 PYRs in the matched background cohort with a difference of 0.40 (95% CI 0.18-0.62) per 1000 PYRs (Table II) . Nadir, but not current CD4 cell count, was associated with a decreased risk of SCC (Table III) . The increased risk of SCC was observed in both MSM as well as HIV patients reporting heterosexual route of HIV transmission (Table II) .
Risk of MM
The risk of developing MM seemed not to be increased 
DISCUSSION
In this nationwide, population-based cohort study we observed a 2-fold increased risk of BCC and a 5-fold increased risk of SCC in patients with HIV compared with the background population. The increased risk of BCC was restricted to patients reporting MSM as route of HIV infection. There seemed to be an association between immunosuppression and SCC risk for patients with HIV. The risk of MM was not increased when compared with the background population, but the low number of MM cases makes a definitive conclusion difficult.
One of the main risk factors for developing skin cancer is exposure to ultraviolet light. In our study, we assumed that skin type and level of sun exposure in childhood were comparable between siblings. We found no increase in BCC, SCC, or MM risk among siblings of patients with HIV compared with siblings of the matched background cohort; therefore, the data did not support confounding by sun exposure in early childhood as an explanation of the increased risk of BCC and SCC among patients with HIV.
However, the use of sunbeds mostly occurs in youth/adulthood, and this use might differ between siblings. Therefore, an increased risk of KSC in patients with HIV, but not their siblings, could be a result of either the immunosuppression caused by the HIV infection or sunbed use in youth/adulthood. The increased risk of BCC was only seen in patients reporting MSM as route of infection. One could argue that the increased risk of BCC might be driven primarily by sun exposure in youth/adulthood not accounted for by the sibling model because previous data suggest that MSM infected with HIV might have an increased recreational ultraviolet light exposure. 12 In addition, no association between BCC and immunosuppression was observed. Difference in lifestyle habits including traveling as well as occupation might also influence the risk; however, data on these parameters were not available for this study. The picture was somewhat the opposite for SCC, which seemed to be associated with more severe immunosuppression as reflected by lower nadir CD4 cell count. In addition, the increased SCC risk was not restricted to any route of infection. This corresponds to data from other studies in individuals with HIV and in solid organ transplant recipients, where the incidence of SCC has been reported to be proportional to the level of immunosuppression. 5, 14, 15 Our results were somehow contradictory in terms of CD4 cell count with nadir, but not current CD4 cell count being associated with risk of SCC. We cannot conclude meaningfully on current CD4 cell count because of the wide CI, but it could be hypothesized that nadir CD4 count is indicative of immunosuppressive history and represents a time lag between immunosuppression and skin cancer while this exposure lag is not seen with current CD4 cell counts.
Human papillomavirus-a is associated with cervical, anogenital, and oropharyngeal cancers. Human papillomavirus-b has been detected in a proportion of cutaneous SCC, and a possible etiologic role has been suggested, especially in the immunosuppressed individuals. However, no mechanism of carcinogenesis has been found. 16, 17 A study from California found a 2.6-fold increased risk of SCC and a 2.1-fold increased risk of BCC when Table II Cumulative incidence of BCC (%)
Years since study inclusion comparing HIV-positive with HIV-negative patients. 5 The risk of BCC was almost comparable to our results, while the risk of SCC was substantially higher in our study. Numerous factors could affect rates of SCC among both patients with HIV and their HIVnegative counterparts, which in turn will affect the estimated relative risk of SCC comparing these 2 groups. In the study from California, SCCs in situ were included. In addition, the Californian cohort was older and had a higher CD4 cell countdthe latter probably contributes substantially to the lower risk of SCC observed in the American study. Unknown and residual confounding as well as unrecognized interaction between HIV and confounders might also affect the associations found. Finally, differences in sun exposure and skin type between California and Denmark might influence the results, but one would expect this to apply for both patients with HIV and control subjects. Our study was not designed to address the potential effect of skin cancer prevention in patients with HIV. In a hypothetical scenario in which prevention reduced the incidence of KSC to that of the background population, the cohort of patients with HIV would have to be observed for approximately 1000 PYRs to avoid 1 case of BCC and 2500 PYRs to avoid 1 case of SCC.
The major strengths of our study are the nationwide, population-based design with long follow-up, and the high quality and almost complete coverage of Danish registries. In addition, potential confounding from family-related factors, such as skin type and sun exposure in childhood, is addressed by comparing siblings. Finally, we matched patients with HIV and the matched background cohort on country of origin (Denmark), reducing the potential bias introduced by differences in skin type between the 2 cohorts.
A limitation of our study is our reliance on registerbased diagnoses without additional validation. A comprehensive assessment has demonstrated that the completeness and validity of the DCR is very high (95-98%). 18 Although we included [4000 patients with HIV with long-term follow-up, we only observed small numbers of SCC and MM, limiting the power of our study and hindering more elaborate stratification. Finally, surveillance bias because of frequent consultations among patients with HIV might contribute to the association between KSC and HIV. However, a short-term (positive) association caused by diagnostic bias alone would be followed by a later compensatory negative association (eg, a KSC risk \1 during extended follow-up), which was not found. Therefore, we do not believe that diagnostic bias alone explains our findings.
In conclusion, with this nationwide, populationbased cohort study, we have shown that patients with HIV have an increased risk of BCC and SCC. The low number of MMs in our study mean that a solid conclusion cannot be made regarding the risk of MM in patients with HIV. The risk of SCC seemed to increase with increasing level of immunosuppression, while the increased risk of BCC was restricted to patients reporting MSM as route of infection. Cumulative incidence of SCC (%)
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